Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of ABBV-903 Formulations in Healthy Volunteers
NCT06078202Phase 1Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of limnetrelvir in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Observed Plasma Concentration and 6 more. Planned start Dec 2024; status: withdrawn.
02
Drugs
limnetrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06078202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078202.